Welcome to the international HTA database

Showing [20001 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2007	HAYES, Inc.	Ureteral bulking agents for vesicoureteral reflux disease
2014	Center for Evidence-based Practice (CEP)	Urinalysis and urine culture specimens taken from old versus new urinary catheters in patients with suspected urinary tract infection
2010	HAYES, Inc.	Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment
2010	HAYES, Inc.	Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment
2001	Health Council of the Netherlands Gezondheidsraad (GR)	Urinary incontinence - review, expert panel
2006	National Institute for Health and Clinical Excellence (NICE)	Urinary incontinence: the management of urinary incontinence in women
2008	Medical Services Advisory Committee (MSAC)	Urinary metabolic profile
2008	Medical Services Advisory Committee (MSAC)	Urinary metabolic profiling for detection of metabolic disorders
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine based testing for gonorrhea and chlamydia: a review of diagnostic accuracy, cost-effectiveness, and compliance
2013	Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2010	Center for Evidence-based Practice (CEP)	Urine drug screening in chronic pain patients on opioid therapy
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: clinical and cost effectiveness
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Urine testing in long-term care: guidelines
2020	NIHR Health Technology Assessment programme	Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT
2017	HAYES, Inc.	Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2016	HAYES, Inc.	UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2011	HAYES, Inc.	UroLume urethral stent (American Medical Systems Inc.) for urinary obstruction secondary to benign prostatic hyperplasia (BPH)
2016	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ursodeoxycholic acid (Ursofalk®)
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2020	NIHR Health Technology Assessment programme	Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2006	Adelaide Health Technology Assessment (AHTA)	USCOM cardiac output monitor for patients requiring haemodynamic monitoring
2005	Adelaide Health Technology Assessment (AHTA)	USCOM cardiac output monitor for ultrasonic cardiac output measurement in patients requiring haemodynamic monitoring
2006	Alberta Heritage Foundation for Medical Research (AHFMR)	USCOM for cardiac output monitoring
2007	Adelaide Health Technology Assessment (AHTA)	USCOM: Ultrasound cardiac output monitor for patients requiring haemodynamic monitoring
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of adalimumab (Humira®) within NHS Wales
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of agalsidase beta (Fabrazyme®) within NHS Wales
2007	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of alglucosidase alfa (Myozyme™) within NHS Wales
2010	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment
2013	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2015	HAYES, Inc.	Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of antipsychotics and/or benzodiazepines as rapid tranquilization in inpatients of mental facilities and emergency departments: a review of the clinical effectiveness and guidelines
2005	Health Council of the Netherlands Gezondheidsraad (GR)	Use of antiviral agents and other measures in an influenza pandemic
2011	Medical Services Advisory Committee (MSAC)	Use of artificial disc replacement in patients with cervical degenerative disc disease
2007	Agency for Healthcare Research and Quality (AHRQ)	Use of aspirin and NSAIDs to prevent colorectal cancer; an evidence synthesis
2005	Medical Advisory Secretariat (MAS)	Use of automated external defibrillators in cardiac arrest - health technology literature review
2005	Medical Advisory Secretariat (MAS)	Use of automated external defibrillators in cardiac arrest: an evidence-based analysis
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of azathioprine in adults: safety
2021	Ontario Health	Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2009	Agency for Healthcare Research and Quality (AHRQ)	Use of Bayesian techniques in randomized clinical trials: a CMS case study
2016	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of biventricular pacing in atrioventricular heart block
2005	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of Bortezomib (Velcade®) within NHS Wales
2007	Agency for Health Technology Assessment in Poland (AHTAPol)	Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
2001	Health Technology Advisory Committee (HTAC)	Use of botulinum toxin-A in pain associated with neuromuscular disorders
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of botulinum toxine in the clinical practice
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of bupropion in patients with depression and the associated risk of seizures: safety
1995	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Use of calcitonin in idiopathic osteoporosis
2004	Alberta Heritage Foundation for Medical Research (AHFMR)	Use of cannabis or cannabinoids for non-malignant chronic pain
2015	Agency for Healthcare Research and Quality (AHRQ)	Use of cardiac resynchronization therapy in the Medicare population
2004	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of carmustine implants (GLIADEL wafer) in patients with malignant glioma at The McGill University Health Centre
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Use of CDET gamma-cameras for conventional scintigraphy (systematic review, primary research, expert panel)
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of cetuximab (Erbitux®) within NHS Wales
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of chlorhexidine gluconate with alcohol for the prevention of peripheral intravenous device infections: a review of clinical and cost effectiveness, and guidelines
2000	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials
2008	Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS)	Use of class 3b and class 4 lasers and intense pulsed light sources for cosmetic procedures in non-medical settings
2009	NIHR Health Technology Assessment programme	Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review
2009	NIHR Health Technology Assessment programme	Use of classical and novel biomarkers as prognostic risk factors for prostate cancer: a systematic review
2010	Medical Advisory Secretariat (MAS)	Use of contrast agents with echocardiography in patients with suboptimal echocardiography
2014	Blue Cross Blue Shield Association (BCBS)	Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of diuretics for hypertension in patients with reduced renal function: a review of clinical effectiveness, safety, and guidelines
2015	NIHR Health Technology Assessment programme	Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)
2002	Blue Cross Blue Shield Association (BCBS)	Use of epithelial cell cytology in breast cancer risk assessment and high-risk patient management
2001	Agency for Healthcare Research and Quality (AHRQ)	Use of epoetin for anemia in chronic renal failure
2017	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of extracorporeal membrane oxygenation for cardiac life support in adult subjects
2006	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Use of FDG-PET in clinical situations not addressed in the monitorized use of this technology. IPE-06/49
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of fentanyl and continuous electronic fetal monitoring in labour and delivery: a review of clinical effectiveness, safety, and clinical practice guidelines
2005	Andalusian Health Technology Assessment Area (AETSA)	Use of flash sterilization
2014	NIHR Health Technology Assessment programme	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey
2007	Blue Cross Blue Shield Association (BCBS)	Use of GeneSearch breast lymph node assay to detect sentinel node metastases in early stage breast cancer
2003	Agency for Healthcare Research and Quality (AHRQ)	Use of glycated hemoglobin and microalbuminuria in the monitoring of diabetes mellitus
2003	Norwegian Knowledge Centre for the Health Services (NOKC)	Use of hematopoietic stem cells from cord blood
2007	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of iloprost trometamol (Ventavis®) within NHS Wales
2005	Blue Cross Blue Shield Association (BCBS)	Use of implantable cardioverter-defibrillators for prevention of sudden death in patients at high risk for ventricular arrhythmia
2002	Blue Cross Blue Shield Association (BCBS)	Use of implantable cardioverter-defibrillators for prevention of sudden death in patients at high risk for ventricular arrhythmia
1999	Alberta Heritage Foundation for Medical Research (AHFMR)	Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer
2003	Blue Cross Blue Shield Association (BCBS)	Use of intermittent or continuous interstitial fluid glucose monitoring in patients with diabetes mellitus
2002	Blue Cross Blue Shield Association (BCBS)	Use of intermittent or continuous interstitial fluid glucose monitoring in patients with diabetes mellitus
2009	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of lidocaine on adults with open wounds: a review of the safety
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of liposomal cytarabine (DepoCyte®) within NHS Wales
2001	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Use of mammography and Papanicolaou's test for the early detection of breast and uterine cervix cancer in Spain. IPE-02/34 (Public report)
2009	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of matrix coils in the treatment of cerebro-vascular aneurysms: an update
2013	Center for Evidence-based Practice (CEP)	Use of midodrine with vasopressors in the intensive care unit
2006	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of mycophenolic acid as a sodium salt (Myfortic®) within NHS Wales
2013	Agency for Healthcare Research and Quality (AHRQ)	Use of natriuretic peptide measurement in the management of heart failure
2013	HAYES, Inc.	Use of negative-displacement needleless connectors and rates of catheter-related bloodstream infections
2013	HAYES, Inc.	Use of neutral-displacement needleless connectors and rates of catheter-related bloodstream infections
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Use of new versus refurbished surgical tables: comparative clinical effectiveness and guidelines
2013	HTA Unit, University of Calgary	Use of Oncotype DX for guiding adjuvant chemotherapy decisions in early stage invasive breast cancer patients in Alberta
2010	Center for Evidence-based Practice (CEP)	Use of opioids for treating chronic back pain
2010	Center for Evidence-based Practice (CEP)	Use of opioids for treatment of fibromyalgia
2003	Norwegian Knowledge Centre for the Health Services (NOKC)	Use of palliative surgery in the treatment of cancer patients
2005	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Use of Pegvisomant (Somavert®) within NHS Wales
2016	Belgian Health Care Knowledge Centre (KCE)	Use of pneumococcal vaccines in the elderly an economic evaluation
2009	Belgian Health Care Knowledge Centre (KCE)	Use of point-of care devices in patients with oral anticoagulation: a health technology assessment
2009	Belgian Health Care Knowledge Centre (KCE)	Use of point-of-care devices in patients with oral anticoagulation : a Health Technology Assessment
1999	Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)	Use of polymerase chain reaction
2013	HAYES, Inc.	Use of positive-displacement needleless connectors and rates of catheter-related bloodstream infections
2001	Agency for Healthcare Research and Quality (AHRQ)	Use of positron emission tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia
2006	Finnish Office for Health Care Technology Assessment (Finohta)	Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review
2007	Andalusian Health Technology Assessment Area (AETSA)	Use of recombinant human erythropoietin in orthopedic surgery